NFKB1 and lung carcinoma: The aim of our study was to investigate whether metformin could inhibit NF-κB signaling in EGFR-mutant lung cancer, and if so, whether it could have anticancer effects on lung cancer and anti-resistance efficacy against acquired EGFR TKIs resistance and underlying mechanisms.